New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2012
12:12 EDTSNX, BMY, CVX, TYC, AMLN, RDS.A, ALIM, PNR, BNNY, XOMOn The Fly: Mid-Day Wrap
Stocks on Wall Street are lower at mid-day, after a report on durable goods orders in February fell short of expectations. After a meandering start to the session the averages have found their direction and it is lower. Each of the major equity indices is firmly in negative territory and at session lows. The market began the session mixed and seemed unaffected by the generally in-line durable goods orders report. The market also ignored the weekly DOE energy inventory reports until the averages broke out of their tight range and moved to the downside, gaining negative momentum as the day progresses... ECONOMIC EVENTS: In the U.S., durable goods orders for February rose 2.2%, versus expectations for a 3.0% increase. The core reading, which excludes transportation items, increased 1.6%, versus the expected increase of 1.7%... MARKET NEWS: Exxon Mobil (XOM), Shell (RDS.A), BP (BP), and Chevron (CVX) all declined as oil prices dropped following statements from France's energy minister about a possible joint oil reserve release coordinated between France, the U.S. and the U.K... Organic pasta maker Annie's (BNNY) soared after the company's initial public offering, which priced above its expected range at $19. The stock is up almost 72% to $32.63 near noon... MAJOR MOVERS: Among the notable gainers were Amylin (AMLN), after Bloomberg reported that the company rejected a $22 per share takeover offer from Bristol-Myers (BMY) earlier this year, and Pentair (PNR), after the company agreed to merge with Tyco's (TYC) Flow Control business to create a combined company that sees pro forma 2012 revenues of $7.7B. Noteworthy losers included SYNNEX (SNX), following a downgrade at Citigroup on the company's disappointing guidance for Q2, and Alimera (ALIM), after the company said last night that based on recent discussions with European regulatory authorities it thinks it will take longer than originally anticipated to obtain marketing authorizations for it ILUVIEN drug... INDICES: Near noon, the Dow was down 83.97, or 0.64%, to 13,113.76; the Nasdaq was down 24.20, or 0.78%, to 3,096.15; and the S&P 500 was down 11.26, or 0.80%, to 1,401.26.
News For A;CVX;BNNY;AMLN;BMY;PNR;TYC;SNX;ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 26, 2015
08:31 EDTBMYAlexandria Real Estate announces lease with Bristol-Myers in Cambridge
Subscribe for More Information
07:35 EDTSNX, SNXSYNNEX downgraded to Outperform from Buy at CLSA
Subscribe for More Information
07:30 EDTSNXSYNNEX downgraded to Hold from Buy at Needham
Needham downgraded SYNNEX to Hold citing the mixed Q2 report and disappointing guidance.
07:27 EDTSNXSYNNEX pullback a buying opportunity, says Citi
Subscribe for More Information
07:21 EDTSNXSYNNEX operating margins should expand later in year, says Brean Capital
Subscribe for More Information
June 25, 2015
19:04 EDTSNXOn The Fly: After Hours Movers
Subscribe for More Information
17:47 EDTSNXSYNNEX optimistic on U.S., Japan market demand
Subscribe for More Information
16:07 EDTSNXSYNNEX sees Q3 EPS $1.40-$1.45, consensus $1.67
Sees Q3 revenue $3.3B-$3.4B, consensus $3.53B. The company anticipates a negative currency impact on revenue of approximately $120M in Q3.
16:06 EDTSNXSYNNEX reports Q2 EPS $1.55, consensus $1.53
Reports Q2 revenue $3.25B, consensus $3.42B. Reports Q2 non-GAAP operating margin of 3.22%, up 35 bps from the prior year quarter's 2.87%.
15:04 EDTSNXNotable companies reporting after market close
Subscribe for More Information
13:08 EDTCVXPenn Virginia higher after blog speculates on another deal
Subscribe for More Information
12:07 EDTCVXBP said to make $8/share bid for Penn Virginia, Proactive Investors blog says
BP (BP) has made a $8 per share takeover bid for Penn Virginia (PVA), but the latter rejected the bid and is "holding out" for at least $10 per share, UK investor blog Proactive Investors claimed, citing people familiar with the matter. ExxonMobil (XOM) and Chevron (CVX) may also be interested in buying Penn Virginia, according to Proactive, which identifies itself as a "leading multi-media news organisation, investor portal and events management business." Penn Virginia shares are up 7% in midday trading following the report from the blog, which was previously credited for a report on alleged takeover advances made toward drugmaker Receptos (RCPT). Reference Link
09:34 EDTBMYBristol-Myers expects Waltham site to close in early 2018
Subscribe for More Information
09:34 EDTCVXActive equity options trading on open
Active equity options trading on open: AAPL FB NFLX AMZN BAC CVX TWTR INTC GILD BBBY
09:32 EDTBMYBristol-Myers opens research site in Cambridge, discontinues virology research
Subscribe for More Information
June 24, 2015
11:29 EDTSNXSYNNEX to host analyst day
Subscribe for More Information
07:29 EDTBMYFDAnews to hold a summit
Subscribe for More Information
07:19 EDTCVXU.K. panel to decide on first fracking in area since 2011, WSJ reports
Subscribe for More Information
June 22, 2015
08:52 EDTBMYPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
05:35 EDTBMYAllied-Bristol Life Sciences licenses IP from Harvard University
Allied-Bristol Life Sciences, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb, announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitmanís lab at the Harvard School of Dental Medicine. Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Childrenís Hospital, Professor Whitmanís lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases. The licensing agreement with Harvardís Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitmanís lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use